PMID- 25168752
OWN - NLM
STAT- MEDLINE
DCOM- 20150320
LR  - 20211021
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 191
IP  - 1
DP  - 2015 Jan
TI  - Clinical and dosimetric evaluation of RapidArc versus standard sliding window 
      IMRT in the treatment of head and neck cancer.
PG  - 43-50
LID - 10.1007/s00066-014-0742-x [doi]
AB  - BACKGROUND: Several planning studies have already proven the substantial 
      dosimetric advantages of RapidArc (RA) over standard intensity-modulated 
      radiotherapy. We retrospectively compared RapidArc and standard sliding window 
      IMRT (swIMRT) in locally advanced head and neck cancer, looking both at 
      dosimetrics as well as toxicity and outcome. METHODS: CT datasets of 78 patients 
      treated with swIMRT and 79 patients treated with RA were included. To compare the 
      resulting dose distributions, the dose-volume parameters were evaluated for the 
      planning target volumes (PTVs), clinical target volumes (CTVs), and organs at 
      risk (OARs), and the number of MU were calculated. Acute toxicity was assessed by 
      the Common Toxicity Criteria version 3.0. RESULTS: PTV coverage with the 95% 
      isodose was slightly better for RA. Dose distribution has proven to be 
      significantly more homogenous with RA and led to a reduction of 62% in MU with 
      better OAR sparing. As for toxicity, more grade 3 mucositis and dysphagia was 
      observed for swIMRT, though we observed more grade 3 dermatitis for RA. 
      CONCLUSION: In our retrospective analysis, RA had better target coverage and 
      better sparing of the OAR. Overall, the grade of acute toxicity was lower for RA 
      than for swIMRT for the same types of tumor locations, except for the grade of 
      dermatitis.
FAU - Smet, Stephanie
AU  - Smet S
AD  - Department of Radiation Oncology, University Hospitals Leuven, Herestraat 49, 
      3000, Leuven, Belgium, stephanie_smet99@hotmail.com.
FAU - Lambrecht, Maarten
AU  - Lambrecht M
FAU - Vanstraelen, Bianca
AU  - Vanstraelen B
FAU - Nuyts, Sandra
AU  - Nuyts S
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140829
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Belgium
MH  - *Body Burden
MH  - Comorbidity
MH  - Female
MH  - Head and Neck Neoplasms/*mortality/*radiotherapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Radiation Injuries/*mortality
MH  - Radiometry/*statistics & numerical data
MH  - *Radiotherapy Dosage
MH  - Radiotherapy Planning, Computer-Assisted/statistics & numerical data
MH  - Radiotherapy, Intensity-Modulated/classification/*statistics & numerical data
MH  - Risk Factors
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2014/08/30 06:00
MHDA- 2015/03/21 06:00
CRDT- 2014/08/30 06:00
PHST- 2014/04/16 00:00 [received]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/08/30 06:00 [entrez]
PHST- 2014/08/30 06:00 [pubmed]
PHST- 2015/03/21 06:00 [medline]
AID - 10.1007/s00066-014-0742-x [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2015 Jan;191(1):43-50. doi: 10.1007/s00066-014-0742-x. Epub 
      2014 Aug 29.